Idelvion (Albutrepenonacog Alfa)

Albutrepenonacog alfa is a recombinant factor VIII fused to the Fc portion of IgG1. The Fc fragment binds to the neonatal Fc receptor, prolonging the circulating half‑life of the molecule, while the factor VIII domain restores deficient clotting activity, enabling the intrinsic coagulation cascade to generate thrombin and form stable fibrin clots.

The dose of Idelvion is individualized. A qualified prescriber determines the amount and frequency based on the patient’s weight, severity of hemophilia A, bleeding history, and clinical response. Dosing regimens are not standardized and should follow the prescribing information and specialist guidance.

Safety data for Idelvion in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss the uncertainties and consider alternative therapies when appropriate.

To order Idelvion, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details—including cold‑chain handling if needed—and assist with import documentation.

Idelvion’s Fc‑fusion design extends its plasma half‑life compared with standard factor VIII concentrates, allowing less frequent infusions for prophylaxis. This can improve adherence and quality of life. Efficacy in controlling bleeds is comparable, but individual response and inhibitor risk should be evaluated when selecting therapy.

Idelvion must be stored refrigerated at 2 °C to 8 °C. Protect the solution from light, do not freeze, and avoid shaking the vial. If temporary temperature excursions occur, discard the product according to the manufacturer’s guidelines.

Idelvion is given by intravenous infusion under the supervision of a qualified healthcare professional. The solution is diluted as instructed and infused over the recommended period, typically ranging from a few minutes to an hour, depending on the clinical setting and patient tolerance.

The most serious adverse events include the development of neutralizing inhibitors against factor VIII, severe allergic reactions such as anaphylaxis, and rare thromboembolic complications. Patients should be monitored closely for signs of these reactions during and after infusion, and immediate medical attention is required if they occur.

Idelvion is contraindicated in individuals with known hypersensitivity to albutrepenonacog alfa or any of its excipients, and in patients who have active, high‑titer factor VIII inhibitors. Caution is also advised for those with a history of severe allergic reactions to blood‑derived products.